Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Gross Profit (2022 - 2025)

Atara Biotherapeutics' Gross Profit history spans 4 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Gross Profit fell 94.26% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $99.6 million, down 7.76%, while the annual FY2025 figure was $99.6 million, 7.76% down from the prior year.
  • Gross Profit reached $1.5 million in Q4 2025 per ATRA's latest filing, down from $3.3 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $77.7 million in Q1 2025 to a low of -$2.1 million in Q2 2023.
  • Average Gross Profit over 4 years is $16.9 million, with a median of $5.9 million recorded in 2022.
  • Peak YoY movement for Gross Profit: tumbled 110.7% in 2023, then surged 6931.87% in 2024.
  • A 4-year view of Gross Profit shows it stood at $221000.0 in 2022, then surged by 365.61% to $1.0 million in 2023, then soared by 2422.64% to $26.0 million in 2024, then plummeted by 94.26% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Gross Profit are $1.5 million (Q4 2025), $3.3 million (Q3 2025), and $17.0 million (Q2 2025).